Specify Company / Ticker to Get the Summary
Dividend History PYPD
Dividend Analytics PYPD
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–PolyPid
PYPDPolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. Address: 18 Hasivim Street, Petah Tikva, Israel, 4959376
Analytics
WallStreet Target Price
12.75 USDP/E Ratio
–Dividend Yield
–Financials PYPD
Results | 2019 | Dynamics |